Saturday 17 October 2026
Export YARW’s income statement to Excel — free account
Yarrow Bioscience, Inc
YARW Healthcare Biotechnology
Yarrow Bioscience, Inc’s revenue for fiscal 2025 (year ended December 2025) was $570,000.00, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 40.6%, EPS grew 67.1% and free cash flow grew 81.6%, each against the same quarter a year earlier.
18.78
1.22
−6.10%
Follow YARW
| Dec '19 | Jan '20 | Dec '20 | Jan '21 | Dec '21 | Jan '22 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
1 | — | 3 | — | 4 | — | 3 | 4 | 2 | 3 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(7.07) | — | (14.10) | — | (12.74) | — | (24.14) | (8.20) | (10.78) | (31.09) |
P/S ratio |
36.13 | 33.48 | 9.75 | 10.00 | 56.40 | 62.48 | 16.47 | 55.25 | 284.78 | 43.52 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(16.32) | — | (32.51) | — | (27.84) | — | (50.58) | (8.74) | (31.45) | (70.34) |
P/Operating CF |
(5.03) | (4.66) | (8.07) | (8.27) | (5.24) | (5.81) | (1.63) | (4.56) | (15.85) | (6.59) |
Beneish M-Score |
— | — | 35.23 | — | 6.27 | — | — | — | — | — |
P/B ratio |
6.37 | 5.90 | 5.46 | 5.60 | 1.08 | 1.20 | 0.25 | 0.26 | 2.74 | 0.89 |
Dividend Safety Score |
— | — | — | — | — | — | — | — | — | 20 |
Price to Tangible BV |
6.37 | 5.90 | 6.12 | 6.28 | 1.18 | 1.30 | 0.29 | 0.28 | 2.97 | 1.05 |
EV/Sales |
23.23 | 20.59 | 8.54 | 8.79 | 81.96 | 17.66 | 91.25 | (7.62) | 295.03 | 109.56 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.00 | 0.00 |
EV/Operating CF |
(0.98) | (0.87) | (1.31) | (1.35) | (1.35) | (0.29) | (1.49) | 0.13 | (4.35) | (1.89) |
EV/FCF |
(0.97) | (0.86) | (1.31) | (1.34) | (1.35) | (0.29) | (1.48) | 0.13 | (4.33) | (1.87) |
Quick Ratio |
2.51 | 3.51 | 3.46 | 2.74 | 2.74 | 3.87 | 3.31 | 12.38 | 4.15 | 12.11 |
Current Ratio |
2.61 | 4.07 | 4.01 | 3.43 | 3.43 | 4.10 | 4.10 | 12.73 | 4.35 | 12.53 |
Net Debt/EBITDA |
0.43 | 0.27 | 0.13 | 1.10 | 1.10 | 0.91 | 0.91 | 3.16 | 1.34 | 0.95 |
Debt/Assets |
40.32% | 36.30% | 35.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
1.86 | 0.91 | 0.88 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.24 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
Operating CF/Net income |
0.77 | 0.54 | 0.54 | 0.77 | 0.77 | 0.81 | 1.26 | 0.89 | 0.85 | 1.25 |
Capex/Depreciation |
(2.91) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 |
Interest Coverage |
(104.10) | — | (57.53) | — | (6.94) | — | — | — | — | — |
| (128.66%) | 0.00% | (928.19%) | 0.00% | (170.28%) | 0.00% | (58.14%) | (47.44%) | (56.57%) | (66.33%) | |
| (86.10%) | 0.00% | (292.24%) | 0.00% | (91.21%) | 0.00% | (43.06%) | (41.10%) | (48.40%) | (54.57%) | |
ROIC |
0.00% | 0.00% | (1,406.53%) | 0.00% | (420.68%) | 0.00% | (9,442.46%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(190.46%) | (376.15%) | (386.94%) | (162.48%) | (162.48%) | (124.88%) | (80.23%) | (32.18%) | (80.10%) | (95.59%) |
Average Days of Receivables |
111.23 | 275.04 | 275.04 | 2,972.93 | 2,972.93 | 3,958.38 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
11,558.01% | 207.37% | 207.37% | 2,099.14% | 2,099.14% | 3,854.30% | 3,854.30% | 3,845.99% | 6,176.85% | 3,374.91% |
Selling, General and Administrative Expense of Revenue |
10,183.75% | 334.13% | 426.54% | 2,168.64% | 2,180.34% | 3,420.34% | 3,435.43% | 3,154.48% | 2,633.13% | 1,944.21% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1,104.97% | 0.00% | 86.22% | 0.00% | 867.88% | 0.00% | 900.84% | 779.48% | 659.28% | 404.91% |
Graham Net Nets |
0.11 | 0.12 | 0.15 | 0.15 | 0.85 | 0.77 | 3.66 | 3.71 | 0.35 | 1.11 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(38.45%) | (41.49%) | (154.78%) | (150.96%) | (141.06%) | (127.33%) | (302.79%) | (308.77%) | (28.06%) | (105.64%) |
Free Cash Flow Yield |
(66.49%) | (71.75%) | (67.00%) | (65.35%) | (107.56%) | (97.09%) | (373.21%) | (108.65%) | (23.94%) | (134.29%) |
Revenue per Share |
47.13 | 11.66 | 583.14 | 0.33 | 16.28 | 0.15 | 7.49 | 2.06 | 0.59 | 0.67 |
Operating CF per Share |
(7,807.87) | (76.11) | (3,807.83) | (19.72) | (985.44) | (9.17) | (458.40) | (123.31) | (39.88) | (38.72) |
Capex per Share |
(108.30) | 0.00 | (3.14) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.14) | 0.00 |
Free Cash Flow per Share |
(7,916.17) | (76.11) | (3,810.97) | (19.72) | (985.44) | (9.17) | (458.40) | (123.31) | (40.02) | (38.72) |
Cash per Share |
7,804.89 | 33.01 | 1,651.25 | 14.99 | 749.21 | 9.72 | 486.26 | 454.05 | 72.22 | 33.91 |
Shareholders Equity per Share |
1,869.68 | 20.82 | 1,041.47 | 17.01 | 850.28 | 9.86 | 489.83 | 431.80 | 61.15 | 32.46 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1,869.68 | 20.82 | 1,041.47 | 17.01 | 850.28 | 9.86 | 489.83 | 431.80 | 61.15 | 32.46 |
Free Cash Flow |
(74.41) | (137.08) | (137.19) | (56.37) | (56.37) | (29.20) | (29.20) | (25.34) | (34.09) | (33.12) |
Working Capital |
47.09 | 65.81 | 65.49 | 44.78 | 44.78 | 28.93 | 28.93 | 88.43 | 49.62 | 27.62 |
Capital Expenditures |
(1.02) | (0.11) | (0.11) | — | — | — | — | — | (0.12) | — |
Net Current Asset Value |
12.83 | 31.01 | 31.01 | 44.78 | 44.78 | 28.93 | 28.72 | 87.01 | 49.62 | 27.62 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.00 | 0.00 |
Capex to Sales |
2.30 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.23 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.12 | 0.16 | 98.53 | 0.31 | 0.31 | 0.00 | 0.00 | 0.00 | (21.58) | (8.39) |
Cash ROIC |
(60.17%) | (104.67%) | (105.44%) | (61.61%) | (61.61%) | (46.80%) | (46.96%) | (13.92%) | (30.01%) | (58.34%) |
Accounts Receivable Turnover |
0.96 | 0.00 | 2.63 | 0.00 | 0.08 | 0.00 | 0.18 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.32 | 0.00 | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 1,253.38 | 1,253.38 | 709.72 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 1,941.42 | 1,941.42 | 794.87 | 794.87 | — | — | — | — | — |
Average Receivables |
0.46 | 7.98 | 7.98 | 11.70 | 11.70 | 6.38 | 2.67 | — | — | — |
Average Payables |
11.32 | 12.07 | 12.07 | 5.65 | 5.65 | 4.45 | 4.45 | 2.02 | 2.18 | 1.87 |
Average Inventory |
1.36 | 4.38 | 4.38 | 7.35 | 7.29 | — | — | — | — | — |
Average Assets |
110.54 | 87.45 | 87.45 | 80.39 | 80.39 | 53.90 | 53.90 | 69.22 | 82.30 | 48.53 |
Average Common Equity |
73.98 | 27.53 | 27.53 | 43.06 | 43.06 | 39.92 | 39.92 | 59.97 | 70.41 | 39.93 |
Columns are period end dates